Skip to main navigation Skip to search Skip to main content

Understanding and managing agitation in neurocognitive disorders: Recent insights and global perspectives

  • Debby L. Gerritsen*
  • , Maarten Van Den Bossche
  • , Alireza Atri
  • , Sanjeda Chumki
  • , Jeffrey Cummings
  • , Ine Declercq
  • , Brent P. Forester
  • , Maria Paula Gastiazoro
  • , Rita Khoury
  • , Mary Michael
  • , Déborah Oliveira
  • , Kiran Rabheru
  • , Edgardo G. Reich
  • , Courtney Zeni
  • , Anne Margriet Pot
  • , George T. Grossberg
  • *Corresponding author for this work
  • Radboud University Medical Center
  • University Hospitals Leuven
  • Harvard University
  • Otsuka Pharmaceutical Co Ltd.
  • University of Nevada, Las Vegas
  • Tufts University
  • Universidad Nacional del Litoral
  • American University of Beirut
  • Universidad Andrés Bello
  • University of Ottawa
  • Universidad de Buenos Aires
  • Axsome pharmaceuticals
  • Saint Louis University School of Medicine

Research output: Contribution to journalReview articleAcademicpeer-review

3 Downloads (Pure)

Abstract

Objectives: Agitation is a common and distressing phenomenon across neurocognitive disorders (NCD). It is linked to decreased quality of life of the person with NCD, cognitive and functional decline, increased health-care utilization and institutionalization rates, and substantial burden for family carers and care professionals. Its management is particularly challenging. The objective of this International Psychogeriatric Association’s (IPA) task force was to synthesize recent advances in nomenclature and assessment, epidemiology, progression, etiology, detection, impact, approaches to managing agitation; and to make recommendations to guide IPA’s next 10-year strategy. Methods: A multidisciplinary expert workgroup met multiple times virtually and during the 2024 IPA Congress in person to discuss the current scientific and clinical practice landscape for agitation in NCD. The group integrated evidence about validated behavioral measures, biomarkers, digital monitoring, psychosocial and environmental interventions, and pharmacological options. Results: Agitation is attributed to disruptions in fronto-limbic circuitry with contributions from neuroimmune dysregulation, neurotransmitter alterations, and mitochondrial dysfunction, and various psychosocial and environmental factors. Psychosocial and environmental strategies can reduce agitation, though magnitude and durability of responses vary. Pharmacological options can have short-term benefits but carry risks that require strict patient selection, counseling, monitoring and medication stewardship. Approved medications based on controlled clinical trials remain limited. Conclusion: Care and support in agitation in NCD should involve the implementation of person-centered, rights-based psychosocial and environmental approaches, with time-limited pharmacological adjuncts as second-line. Key evidence gaps include head-to-head and longer-term trials, active safety surveillance, validated agitation measures, and equity-focused implementation across settings and cultures.

Original languageEnglish
Article number100241
JournalInternational Psychogeriatrics
DOIs
Publication statusE-pub ahead of print - 22 Jul 2026

Bibliographical note

Publisher Copyright:
© 2026 The Author(s). Published by Elsevier Inc. on behalf of International Psychogeriatric Association.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Understanding and managing agitation in neurocognitive disorders: Recent insights and global perspectives'. Together they form a unique fingerprint.

Cite this